beta

ALNA

Allena Pharmaceuticals, Inc.

Alna

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes Reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.

Market Cap: 54.4 Million

Primary Exchange: NASDAQ

Website: http://www.allenapharma.com

Shares Outstanding: 23.5 Million

Float: 11.4 Million

Dividend: (%)

Beta: 1.55248128578515

Sector: Health Technology

Industry: Pharmaceuticals: Major

Ethical Flags

Animal testing

Longest drawdown: 441 trading days

From: 2018-04-04 To: 2019-12-13

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud